Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE...
-
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this...
-
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the...
-
BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble...
-
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc....
-
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma’s pan-viral...
-
BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation...
-
BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and...
-
BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in a fireside chat at the Zacks SCR Life Sciences Virtual Investor...
-
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025 (GLOBE...